Global Bacterial Vaginosis Rx Drug Market By Type (Pills, Gels, Creams, Other Product Types), By Use (Hospitals, Clinics), By Region, and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2021-2031

Bacterial Vaginosis (BV), also known as non-specific vaginitis, is a vaginal condition caused by an overgrowth of certain bacteria in the vagina that causes vaginal discharge. Gardnerella vaginitis was the previous term for this condition, which was named after the bacteria that was thought to cause it.

However, it is now known as bacterial vaginosis, which refers to the fact that multiple kinds of bacteria naturally dwell in the vaginal area and can proliferate to excess, rather than infection with foreign bacteria, as many Sexually Transmitted Diseases (STDs) do.

Symptoms of bacterial vaginosis include itching, discharge, odor, and discomfort in the vulvovaginal area. More than 84% of women with bacterial vaginosis exhibit no symptoms, according to the Centers for Disease Control and Prevention (CDC). It's a frequent genital tract disorder among women of reproductive age, and it's the leading source of vaginal discharge and odor.

Request Covid - 19 Impact

Preterm Premature Rupture Of Membranes (preterm PROM), preterm birth and labor, spontaneous abortion, postpartum endometritis, postsurgical infections, post-cesarean-delivery wound infections, and subclinical pelvic inflammatory disease are all possible complications of bacterial vaginosis.

An extraordinary amount of vaginal discharge, thin and greyish white vaginal discharge and vaginal odor are all indications of bacterial vaginosis. Bacterial Vaginosis can also be caused by a number of risk factors that have been discovered. Antibiotic usage, intrauterine devices for birth control, and cigarette smoking are all risk factors for BV.

Bacterial vaginosis can be detected with a vaginal swab test, and it is treated with antibiotics, vaginal gels, and lotions that modify the pH of the vagina.

Detailed Segmentation –

Product Type:

• Pills
• Gels
• Creams
• Other Product Types

End-Use:

• Hospitals
• Clinics

Based on Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Market Dynamics –

Drivers for the Global Bacterial Vaginosis Rx Drug Market:

The increasing incidence of bacterial vaginosis, growing awareness of women's health, and steady development of pharmaceuticals for treatment are all crucial factors driving the global bacterial vaginosis drugs market.

Restraints Global Bacterial Vaginosis Rx Drug Market:

COVID-19 has an impact on the global economy since it directly affects production and demand, disrupts supply chains and marketplaces, and has a financial impact on enterprises and financial markets. This pandemic has had a negative impact on the global bacterial vaginosis medications market, as medical professionals were more focused on catering to patients that suffer from COVID-19, and put off other non-essential forms of treatment for various diseases including BV.

Opportunities for the Global Bacterial Vaginosis Rx Drug Market:

The market for pharmaceuticals connected to diseases among women is expected to index exponential growth in the next years as a result of recent breakthroughs in healthcare, as well as various activities being conducted by respective governments and non-government organizations to raise awareness concerning women's health.

Trends for the Global Bacterial Vaginosis Rx Drug Market:

In underdeveloped nations, the increased prevalence of infectious diseases and the lack of drug laws necessitate public awareness campaigns about antibiotic overuse. In the future, the bacterial vaginosis medications market is expected to gain momentum as public knowledge about the proper use of antibiotics increases.

Competitive Landscape –

• Alkem Labs
• Padagis LLC
• Starpharma Holdings Limited
• AstraZeneca
• Cardinal Health
• Novartis AG
• Bayer AG
• Galderma Canada Inc.
• Pfizer Inc.

Recent Developments of Major Players –

On August 20, 2020, Daré Bioscience Inc., a pioneer in women's health innovation, announced the publication of a proof of concept study of DARE-BV1 in Clinical and Experimental Obstetrics & Gynecology, an international journal dedicated to publishing high-quality scientific research in the fields of obstetrics and gynecology, as well as women's health.

DARE-BV1 is a new thermosetting bio adhesive hydrogel containing 2% clindamycin phosphate that is being tested as a one-time vaginally given bacterial vaginosis treatment.

For the Bacterial Vaginosis Rx Drug Market research study, the following years have been considered to estimate the market size: